Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ADPT 
Adaptive Biotechnologies Corp (ADPT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/06/2025: ADPT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -68.06% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/06/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.14B USD | Price to earnings Ratio - | 1Y Target Price 9.71 |
Price to earnings Ratio - | 1Y Target Price 9.71 | ||
Volume (30-day avg) 1591527 | Beta 1.53 | 52 Weeks Range 2.28 - 9.01 | Updated Date 04/1/2025 |
52 Weeks Range 2.28 - 9.01 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.08 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -89.12% | Operating Margin (TTM) -71.3% |
Management Effectiveness
Return on Assets (TTM) -16.17% | Return on Equity (TTM) -62.49% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 969572931 | Price to Sales(TTM) 6.38 |
Enterprise Value 969572931 | Price to Sales(TTM) 6.38 | ||
Enterprise Value to Revenue 5.42 | Enterprise Value to EBITDA -1 | Shares Outstanding 148582000 | Shares Floating 96477395 |
Shares Outstanding 148582000 | Shares Floating 96477395 | ||
Percent Insiders 2.39 | Percent Institutions 94.01 |
Analyst Ratings
Rating 4.12 | Target Price 7.58 | Buy 3 | Strong Buy 3 |
Buy 3 | Strong Buy 3 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Adaptive Biotechnologies Corp
Company Overview
History and Background
Adaptive Biotechnologies Corp. was founded in 2009. It focuses on immune system diagnostics and therapeutics based on sequencing the adaptive immune system.
Core Business Areas
- Minimal Residual Disease (MRD): ClonoSEQ is its FDA-cleared assay for detecting and monitoring minimal residual disease in patients with certain blood cancers. It offers a sensitive way to assess treatment response and predict relapse.
- Drug Discovery: Leverages its immune medicine platform to discover and develop novel antibody-based therapeutics for various diseases, including cancer and autoimmune disorders. The company uses its platform to identify antibodies that bind to specific targets and can be developed into therapeutic candidates.
Leadership and Structure
The leadership team includes the CEO, CSO, and CFO, along with various VPs heading research, development, and commercial operations. It operates with a matrix structure where functional teams support both MRD and drug discovery activities.
Top Products and Market Share
Key Offerings
- ClonoSEQ: ClonoSEQ is used for MRD assessment in hematologic malignancies. The market share data is difficult to pinpoint exactly but it is considered a leading test in this area. Competitors include Invivoscribe, Asuragen (Bio-Rad).
- Drug Discovery Pipeline: Adaptive is developing various drug candidates based on its immune medicine platform, targeting cancers and autoimmune diseases. Revenue from the drug discovery division is dependent on milestone payments and eventual royalties. Competitors are large pharmaceutical and biotechnology companies.
Market Dynamics
Industry Overview
The industry involves immune system diagnostics and therapeutics, experiencing significant growth driven by advances in sequencing technology and immunotherapy.
Positioning
Adaptive is positioned as a leader in immune-driven medicine with its expertise in sequencing and analyzing the adaptive immune system, leading to a competitive advantage in MRD monitoring and drug discovery.
Total Addressable Market (TAM)
The total addressable market is expected to exceed billions of dollars. Adaptive is strategically positioned to capture a significant share by leveraging its platform to expand MRD applications and therapeutic pipeline.
Upturn SWOT Analysis
Strengths
- Proprietary immune medicine platform
- FDA-cleared ClonoSEQ assay
- Expertise in sequencing and bioinformatics
- Partnerships with leading pharmaceutical companies
Weaknesses
- High operating expenses
- Dependence on ClonoSEQ revenue
- Limited commercialized therapeutic products
- Reliance on partnerships for drug development
Opportunities
- Expansion of ClonoSEQ applications to solid tumors
- Advancement of therapeutic pipeline
- Strategic collaborations and licensing agreements
- Market growth in immune-driven diagnostics and therapeutics
Threats
- Competition from other diagnostic and therapeutic companies
- Regulatory hurdles and reimbursement challenges
- Technological advancements by competitors
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- Invivoscribe (Private)
- Bio-Rad (BIO)
Competitive Landscape
Adaptive's competitive advantage lies in its proprietary platform and FDA-cleared assay. Competitors are active in both MRD monitoring and drug discovery.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Adaptive has experienced steady revenue growth from ClonoSEQ and strategic collaborations.
Future Projections: Analysts project continued revenue growth driven by ClonoSEQ adoption and pipeline advancement.
Recent Initiatives: Adaptive has focused on expanding ClonoSEQ applications, advancing its therapeutic pipeline, and establishing strategic partnerships.
Summary
Adaptive Biotechnologies is strategically positioned in the immune-driven medicine space with a strong technology platform but faces challenges related to profitability. ClonoSEQ has generated growing revenues but the company's heavy R&D spending continues to be a drain on its financials. Success will depend on continued growth of ClonoSEQ, pipeline progression, and partnerships. It should keep a close eye on the competition, regulatory hurdles, and its burn rate.
Similar Companies
- BIO
- ILMN
- PACB
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Company Website
- Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered as financial advice. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adaptive Biotechnologies Corp
Exchange NASDAQ | Headquaters Seattle, WA, United States | ||
IPO Launch date 2019-06-27 | Co-Founder, CEO & Chairman Mr. Chad M. Robins M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 619 | Website https://www.adaptivebiotech.com |
Full time employees 619 | Website https://www.adaptivebiotech.com | ||
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. It has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.